Oncological Applications of Somatostatin Analogues

Cancer Research

Volumn 48, Issue , 2016, Pages 6977-6985

  Schally, Andrew V ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; VAPREOTIDE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMAL; ANTINEOPLASTIC AGENTS; HUMAN; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; SOMATOSTATIN; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0024213731     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (127)

1. Schally, A. V., Coy, D. H., and Meyers, C. A. Hypothalamic regulatory hormones. Annu. Rev. Biochem., 47:89-128, 1978.
2. Reichlin, D. Somatostatin. N. Engl. J. Med., 309:1495-1501,1556-1563, 1983.
3. Mascardo, R. N., and Sherline, P. Somatostatin inhibits rapid centrosomal separation and cell proliferation induced by epidermal growth factor. Endocrinology, 111:1394-1396,1982.
4. Schally, A. V., and Redding, T. W. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc. Natl. Acad. Sci. USA, 84: 7275–7279, 1987.
5. Schally, A. V., Coy, D. H., Murphy, W. A., Redding, T. W., Comaru-Schally, A. M., Hall, R., Rodriguez-Arnao, M. D., Gomez-Pan, A., Gonzalez-Barcena D., Miller, R. P., and Konturek, S. Physiological and clinical studies with somatostatin analogs and pro-somatostatin. In: S. Raptis, J. Rosenthal, and J. E. Gerich (eds.), Second International Symposium on Somatostatin, Athens (Greece), pp. 188–196. Tübingen, Germany: At-tempto Verlag, 1984.
6. Schally, A. V., Cai, R. Z., Torres-Aleman, I., Redding, T. W., Szoke, B., Fu, D., Hierowski, M. T., Colaluca, J., and Konturek, S. Endocrine, gastrointestinal and antitumor activity of somatostatin analogs. In: T. W. Moody (ed.), Neural and Endocrine Peptides and Receptors, pp. 73–83. New York: Plenum Publishing Corp., 1986.
7. Mortimer, C. H., Tunbridge, W. M. G., Carr, D., Yeomans, L., Lind, T., Coy, D. H., Bloom, S. R., Kastin, A., Mallinson, C. N., Besser, G. M., Schally, A. V., and Hall, R. Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet, 1:697-701,1974.
8. Bloom, S. R., Thorner, M. O., Besser, G. M., Hall, R., Gomez-Pan, A., Roy, V. M., Russell, R. C. G., Coy, D. H., Kastin, A. J., and Schally, A. V. Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet, 2:1106-1109,1974.
9. Hall, R., and Gomez-Pan, A. The hypothalamic regulatory hormones and their clinical applications. Adv. Clin. Chem., 18:173-212,1976.
10. Meyers, C., Arimura, A., Gordin, A., Fernandez-Durango, R., Coy, D. H., Schally, A. V., Drouin, J., Ferland, L., Beaulieu, M., and Labrie, F. Somatostatin analogs which inhibit glucagon and growth hormone more than insulin release. Biochem. Biophys. Res. Commun., 74:630-636,1977.
11. Rivier, J., Brown, M., and Vale, W. D-Trp-8-somatostatin: an analog of somatostatin more potent than the native molecule. Biochem. Biophys. Res. Commun., 65:746-751,1975.
12. Meyers, C. A., Coy, D. H., Huang, W. Y., Schally, A. V., and Redding, T. W. Highly active position eight analogues of somatostatin and separation of peptide diastereoisomers by partition chromatography. Biochemistry, 17: 2326-2331,1978.
13. Redding, T. W., and Schally, A. V. Inhibition of growth of the transplantable rat chondrosarcoma by analogs of hypothalamic hormones. Proc. Natl. Acad. Sci. USA, 80:1078-1082,1983.
14. Redding, T. W., and Schally, A. V. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc. Natl. Acad. Sci. USA, 81:248-252, 1984.
15. Schally, A. V., Comaru-Schally, A. M., and Redding, T. W. Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc. Soc. Exp. Biol. Med., 175:259-281,1984.
16. Schally, A. V., Redding, T. W., and Comaru-Schally, A. M. Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat. Rep., 68:281-289,1984.
17. Veber, D. F., Freidinger, R. M., Schwenk-Perlow, D., Paleveda, W. J., Jr., Holly, R. W., Strachan, R. G., Nutt, R. F., Arison, B. H., Homnick, C., Randall, W. C., Glitzer, M. S., Saperstein, R., and Hirchmann, R. A potent cyclic hexapeptide analogue of somatostatin. Nature (Lond.), 292: 55–58, 1981.
18. Veber, D. F., Saperstein, R., Nutt, R. F., Freidinger, R. M., Brady, S. F., Curley, R., Perlow, D. S., Paleveda, W. J., Colton, C. D., Zacchei, A. G., Tocco, D. J., Hoff, D. R., Vandlen, R. L., Gerich, J. E., Hall, L., Mandarino, L., Cordes, E. H., Anderson, P. S., and Hirschmann, R. A superactive cyclic hexapeptide analog of somatostatin. Life Sci., 34:1371-1378,1984.
19. Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., Marbach, P., Petcher, T. J., and Pless, J. SMS-201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci., 31: 1133-1140,1982.
20. Marbach, M., Neufeld, M., and Pless, J. Clinical applications of somatostatin analogs. In: Y. C. Patel and G. S. Tannenbaum (eds.), Somatostatin, pp. 339–353. New York: Plenum Publishing Corp., 1985.
21. Redding, T. W., Schally, A. V., Tice, T. R., and Meyers, W. E. Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp-6]luteinizing hormone-releasing hormone from injectable microcapsules. Proc. Natl. Acad. Sci. USA, 81:5845-5848,1984.
22. Cai, R. Z., Szoke, B., Lu, R., Fu, D., Redding, T. W., and Schally, A. V. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc. Natl. Acad. Sci. USA, 83:1896-1900,1986.
23. Cai, R. Z., Karashima, T., Guoth, J., Szoke, B., Olsen, D., and Schally, A. V. Superactive octapeptide somatostatin analogs containing tryptophan residue in position 1. Proc. Natl. Acad. Sci. USA, 84:2502-2506,1987.
24. Konturek, S. J., Bilski, J., Jaworek, J., Tasler, J., and Schally, A. V. Comparison of somatostatin and its highly potent hexa- and octapeptide analogs on exocrine and endocrine pancreatic secretion. Proc. Soc. Exp. Biol. Med., 187:241-249,1988.
25. Murphy, W. A., Lance, V. A., Moreau, S., Moreau, J.-P., and Coy, D. H. Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin. Life Sci., 40:2515-2522,1987.
26. Hierowski, M. T., Liebow, C., du Sapin, K., and Schally, A. V. Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. FEBS Lett., 179:252-256,1985.
27. Liebow, C., Hierowski, M., and du Sapin, K. Hormonal control of pancreatic cancer growth. Pancreas, 1:44-48,1986.
28. Schally, A. V., Redding, T. W., Cai, R. Z., Paz, J. I., Ben-David, M., and Comaru-Schally, A. M. Somatostatin analogs in the treatment of various experimental tumors. In: J. G. M. Klijn (ed.), International Symposium on Hormonal Manipulation of Cancer Peptides, Growth Factors and New(anti)steroidal Agents, pp. 431–440. New York: Raven Press, 1987.
29. Schally, A. V., Redding, T. W., Paz-Bouza, J. I. Comaru-Schally, A. M., and Mathe, G. Current concept for improving treatment of prostate cancer based on combination of LH-RH aeonists with other aaents. In: G. P. Murphy, S. Khoury, R. Kuss, C. Chatelain, and L. Denis (eds.), Prostate Cancer, Part A, pp. 173–197. New York: Alan R. Liss, 1987.
30. Malarkey, W. B., Kennedy, W. B., Allred, L. E., and Milo, G. Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture. J. Clin. Endocrinol. Metab., 56:673-677,1983.
31. Pearson, O. H., Manni, A., Chambers, M., Brodkey, J., and Marshall, J. S. Role of pituitary hormones in the growth of human breast cancer. Cancer Res., 38:4323-4326,1978.
32. Nilsson, A., Isgaard, J., Lindahl, A., Dahlstrom, A., Skottner, A., and Isaksson, O. G. P. Regulation by growth hormone of number of chondro-cytes containing IGF-I in rat growth plate. Science (Wash. DC), 233: 571—574.1986.
33. Davoren, J. B., and Hsueh, A. J. W. Growth hormone increases ovarian levels of immunoreactive somatomedin C/insulin-like growth Factor I in vivo. Endocrinology, 118:888-890,1986.
34. Zezulak, K. M., and Green, H. The generation of insulin-like growth factor-1-sensitive cells by growth hormone action. Science (Wash. DC), 233:551-553.1986.
35. D'Ercole, A. J., Stiles, A. D., and Underwood, L. E. Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc. Natl. Acad Sci. USA, 81:935-939,1984.
36. Stoscheck, C. M., and King, L. E., Jr. Role of epidermal growth factor in carcinogenesis. Cancer Res., 46:1030-1037,1986.
37. Heldin, C. H., and Westermark, B. Growth factors: mechanism of action and relation to oncogenes. Cell, 37:9-20,1984.
38. Goustin, A. S., Leof, E. B., Shipley, G. S., and Moses, H. L. Growth factors and cancer. Cancer Res., 46:1015-1029,1986.
39. Lippman, M. E., Dickson, R. B., Kasid, A., Gelmann, E., Davidson, N., McManaway, M., Huff, K., Bronzert, D., Bates, E., Swain, S., and Knabbe, C. J. Autocrine and paracrine growth regulation of human breast cancer. J. Steroid Biochem., 24:147-154,1986.
40. Antoniades, H. N., Pantazis, P., Graves, D. T., Owen, A. J., and Tempst, P. Platelet-derived growth factor a link to malignant transformation. In: J. Feramisco (ed.), Cancer Cells 3, pp. 145–151. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1985.
41. Todaro, G. J., Fryling, C., and De Larco, J. E. Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors. Proc. Natl. Acad. Sci. USA, 77; 5258-5262,1980.
42. Paz-Bouza, J. I., Redding, T. W., and Schally, A. V. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA, 84:1112-1116,1987.
43. Cuttitta, F., Carney, D. N., Mulshine, J., Moody, T. W., Fedorko, J., Fischler, A., and Minna, J. D. Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature (Lond.), 316:823-826,1985.
44. Weber, S., Zuckerman, J. E., Bostwick, D. G., Bensch, K. G., Sikic, B. I., and Raffin, T. A. Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro. J. Clin Invest., 75: 306-309,1985.
45. Moody, T. W., Russell, D. K., O'Donohue, T. L., Linden, C. D., and Gazdar, A. F. Bombesin-like peptides in small cell lung cancer biochemical characterization and secretion from a cell line. Life Sci., 32:487-493,1983.
46. Doolittle, R. F., Hunkapiller, M. W., Hood, L. E., Devare, S. G., Robbins, K. C., Aaronson, S. A., and Antoniades, H. N. Simian sarcoma virus one gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science (Wash. DC), 221:275-277,1983.
47. Waterficld, M. D., Scrace, G. T., Whittle, N., Stroobant, P., Johnsson, A., Wastesson, A., Westermark, B., Heldin, C. H., Huang, J. S., and Deuel, T. F. Platelet-derived growth is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature (Lond.), 304: 35-39,1983.
48. Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ulrich, A., Schlessinger, J., and Waterfield, M. D. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature (Lond.), 307:521-527,1984.
49. Iwata, K. K., Fryling, C. M., Knott, W. B., and Todaro, G. J. Isolation of tumor cell growth-inhibiting factors from a human rhabdomyosarcoma cell line. Cancer Res., 45:2689-2694,1985.
50. Hall, R., Besser, G. M., Schally, A. V., Coy, D. H., Evered, D., Goldie, D. J., Kastin, A. J., McNeilly, A. S., Mortimer, C. H., Phenekos, C., Tunbridge, W. M. G., and Weightman, D. Actions of growth hormone-release inhibiting hormone in healthy men and in acromegaly. Lancet, 2:581-584,1973.
51. analogue 51. Plewe, G., Beyer, J., Krause, U., Neufeld, M., and Del Pozo, E. Long-acting and selective suppression of growth hormone secretion by somatostatin SMS 201–995 in acromegaly. Lancet, 2:782-784,1984.
52. Lamberts, S. W. J., Uitterlinden, P., Verschoor, L., van Dongen, K. J., and Del Pozo, E. Long-term treatment of acromegaly with the somatostatin analog SMS 201995. N. Engl. J. Med., 313:1576-1580,1985.
53. Lamberts, S. W. J., Uitterlinde, P., and Del Pozo, E. Sandostatin (SMS 201–995) induces a continuous further decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J. Clin. Endocrinol Metab., 65:703-710,1987.
54. Bernard, L. B., Grantham, W. G., Lamberton, P., O'Dorisio, T. M., and Jackson, I. M. D. Treatment of resistant acromegaly with long-acting somatostatin analogue (SMS 201–995). Ann. Internal Med., 105:856-861
55. Gonzalez-Barcena, D., Castaneda-Dominguez, M., Leon, L., Comaru-Schally, A. M., and Schally, A. V. Inhibition of growth hormone levels in acromegalic patients after administration of a new octapeptide analog of somatostatin. Abstracts of the Endocrine Society Meeting, p. 190, 1987.
56. Comi, R. J., Gesundheit, N., Murray, L., Gorden, P., and Weintraud, B. D. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N. Engl. J. Med., 317:12-17, 1987.
57. Lamberts, S. W. J., Koper, J. W., and Reubi, J. C. Potential role of somatostatin analogues in the treatment of cancer. Eur. J. Clin. Invest., 17: 281–287, 1987.
58. D'Orisio, T. Gut endocrinology: clinical and therapeutic impact. Am. J. Med., 81 (Suppl. 6B); 1-7,1986.
59. Vinik, A. I., and Glaser, B. F. Pancreatic endocrine tumors. In: T. L. Dent (ed.), Pancreatic Disease: Diagnosis and Therapy, pp. 427–460. New York: Grune and Stratton, Inc., 1981.
60. Friesen, S. R. Tumors of the endocrine pancreas. N. Engl. J. Med., 306: 580-590,1982.
61. Kvols, L. D. Metastatic carcinoid tumors and the carcinoid syndrome. Am. J. Med., 81 (Suppl. 6B); 49–53, 1986.
62. Kvols, L. D., Moertel, C. G., O'Connell, M. J., Schutt, A. J., Rudin, J., and Hahn, R. G. Treatment of the malignant carcinoid syndrome. N. Engl. J. Med., 315:663-666,1986.
63. Souquet, J. C., Sassolas, G., Forichon, J., Champetier, P., Partensky, C., and Chayvialle, J. A. Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome. Cancer (Phila.), 59:1654-1660,1987.
64. Mathe, G., Gastiaburu, J., Comaru-Schally, A. M., Schally, A. V., Mauver-nay, R. Y., Cupissol, D., Jasmin, C., and Misset, J. L., Octastatine, an agonist of somatostatin. In: Second International Conference of the Metastasis Research Society, Heidelberg, Germany, September 26-29,1988.
65. Bloom, S. R., and Polak, J. M. Manifestations of pancreatic endocrine tumors. In: F. Labrie and L. Proulx (eds.), Endocrinology, pp. 1095–1101. Amsterdam: Elsevier Scientific Publishers BV, 1984.
66. Long, R. G., Barnes, A. J., Adrian, T. E., Mallinson, C. N., Brown, M. R., Vale, W., Rivier, J. E., Christopides, N. D., and Bloom, S. R. Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue. Lancet, 2:764-767,1979.
67. Ellison, E. C., O'Dorisio, T. M., and Benson, G. D. Modulation of functional gastrointestinal endocrine tumors by endogenous and exogenous somatostatin. Am. J. Med., 151:668-675,1986.
68. Boden, G., Ryan, I. G., Eisenschmid, B. L., Shelmet, J. J., and Owen, O. E. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201995. N. Engl. J. Med., 314:1686-1689,1986.
69. Ellison, E. C., Grower, W. R., Elkhammas, E., Woltering, E. A., Sparks, J., O'Dorisio, T. M., and Fabri, P. J. Characterization of the in vivo and in vitro inhibition of gastrin secretion from gastrinoma by a somatostatin analogue (SMS 201–995). Am. J. Med., 81:56-64,1986.
70. Wood, S. M., Kraenslin, M. E., Adrian, T. E., and Bloom, S. R. Treatment of patients with pancreatic endocrine tumors using a new long-acting somatostatin analogue; symptomatic and peptide responses. Gut, 26: 438-444,1985.
71. Maton, P. N., O'Dorisio, T. M., Howe, B. A., McArthur, K. E., Howard, J. M., Cherner, J. A., Malarkey, T. B., Collen, M. J., Gardner, J. D., and Jensen, R. T. Effect of a long-acting somatostatin analogue (SMS 201995) in a patient with pancreatic cholera. N. Engl. J. Med., 312:17-21, 1985.
72. Kraenzlin, M. E., Ch'ng, J. C., Wood, S. M., and Bloom, S. R. Can inhibition of hormone secretion be associated with endocrine tumour shrinkage? Lancet, 2:1501,1983.
73. Kraenzlin, M. E., Ch'ng, J. C., Wood, S. M., Carr, D. H., and Bloom, S. R. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology, 88:185-187,1985.
74. Santangelo, W. C., O'Dorisio, T. M., Kim, J. G., Serverino, G., and Krejs, G. J. Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport. Ann. Internal Med., 103: 363–367, 1985.
75. Bonfils, A. New somatostatin molecule for management of endocrine tumours. Gut, 26:433-437,1985.
76. Gold, E. B., Gordis, L., Diener, M. D., Seltser, R., Boitnott, J. K., Bynum, T. E., and Hutcheon, D. F. Diet and other risk factors for cancer of the pancreas. Cancer (Phila.), 55:460-467,1985.
77. Malt, R. A. Treatment of pancreatic cancer. JAMA, 250:1433-1437,1983.
78. Theve, N. O., Pousette, A., and Carlstrom, K. Adenocarcinoma of the pancreas-a hormone sensitive tumor? A preliminary report on Nolvadex treatment. Clin. Oncol., 9:193-197,1983.
79. Comaru-Schally, A. M., and Schally, A. V. LH-RH agonists as adjuncts to somatostatin analogs in the treatment of pancreatic cancer. In: B. Lunenfeld and B. Vickery (eds.), International Symposium on Gn-RH Analogues in Cancer and Human Reproduction. Geneva: MTP Press, 1988.
80. Schally, A. V., Bajusz, S., Redding, T. W., Zalatnai, A., and Comaru-Schally, A. M. Analogs of LH-RH: the present and the future. In: B. Lunenfeld and B. Vickery (ed.), International Symposium on Gn-RH Analogues in Cancer and Human Reproduction, Geneva: MTP Press, 1988.
81. Greenway, B. A. Carcinoma of the exocrine pancreas: a sex hormone responsive tumor? Br. J. Surg., 74:441-442,1987.
82. Johnson, L. R. Effects of gastrointestinal hormones on pancreatic growth. Cancer (Phila.), 47:1640-1645,1981.
83. Townsend, C. M., Franklin, R. B., Watson, L. C., Glass, E., and Thompson, 32:228-229, J. Stimulation of pancreatic cancer growth by caerulein and secretin. Surg. 1981.
84. Lhoste, E. F., and Longnecker, D. S. Effect of bombesin and caerulein on early stages of carcinogenesis induced by azaserine in the rat pancreas. Cancer Res., 47:3273-3277,1987.
85. Korc, M., and Magun, B. E. Recycling of epidermal growth factor in a human pancreatic carcinoma cell line. Proc. Natl. Acad. Sci. USA, 82: 6172-6175,1985.
86. Chester, J. F., Gaissert, H. A., Ross, J. S., Malt, R. A. Pancreatic cancer in the Syrian hamster induced by N-nitrosobis(2-oxopropyl)amine: cocarcino-genic effect of epidermal growth factor. Cancer Res., 46:2954-2957,1986.
87. Sandberg, A. A., and Rosenthal, H. E. Steroid receptors in exocrine glands: the pancreas and the prostate. J. Steroid Biochem., 11:293-299,1979.
88. Gonzalez-Barcena, D., Rangel-Garcia, E., Perez-Sanchez, P., Gutierrez-Damperio, C., Garcia Carrasco, F., Comaru-Schally, A. M., and Schally, A. V. 2:154, Response to D-Trp-6-LH-RH advanced adenocarcinoma of pancreas. 1986. Lancet
89. Zalatnai, A., and Schally, A. V. Responsiveness of the hamster pancreatic cancer to treatment with microcapsules of D-Trp-6-LH-RH and somatostatin analog RC-160: histological evidence of improvement. Int. J. Pancreatol., in press, 1988.
90. Singh, P., Walker, J. P., Townsend, C. M., Jr., and Thompson, J. C. Role of gastrin and gastrin receptors on the growth of a transplantable mouse colon carcinoma (MC-26) in BALB/c mice. Cancer Res., 46: 1612–1616, 1986.
91. Elwyn, K. E., Jones, R. D., and Romsdahl, M. N. Inhibitory effects of secretin on gastrin-stimulated rat colon neoplasms. Cancer (Phila.), 55: 1186-1189,1985.
92. Sumiyoshi, H., Yasue, W., Ochiai, A., and Tahara, E. Effects of gastrin on tumor growth and cyclic nucleotide metabolism in xenotransplantable human gastric and colonic carcinomas in nude mice. Cancer Res., 44: 4276-4280,1984.
93. Alford, T. C., Do, H., Geelhoed, G. W., Tsangaris, N. T., and Lippman, M. E. Steroid hormone receptors in human colon cancers. Cancer (Phila.), 43:980-984,1979.
94. Kusyk, C. J., McNiel, N. O., and Johnson, L. R. Stimulation of growth of a colon cancer cell line by gastrin. Am. J. Physiol., 251:597-601,1986.
95. Tricoli, J. V., Rail, L. B., Karakousis, C. P., Herrera, L., Petrelli, N. J., Bell, G. I., and Shows, T. B. Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res., 46:6169-6173,1986.
96. Poliak, M. N., Perdue, J. F., Margolese, R. G., Baer, K., and Richard, M. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett., 38:223-230,1987.
97. Hanauske, A. R., Buchok, J., Scheithauer, W., and Von Hoff, D. D. Human colon cancer cell line secrete a TGF-like activity. Br. J. Cancer, 55: 57–59, 1987.
98. Henderson, B. E., Ross, R. K., Pike, M. C., and Casagrande, J. T. Endogenous hormones as a major factor in human cancer. Cancer Res., 42:3232-3239,1982.
99. Salomon, D. S., Paglia, L. M., and Verbruggen, L. Hormone-dependent growth of a rat chrondrosarcoma in vivo. Cancer Res., 39:4387-4395,1979.
100. McCumbee, W. D., McCarty, K. S., Jr., and Lebovitz, H. E. Hormone responsiveness of a transplantable rat chondrosarcoma. II. Evidence for in vivo hormone dependence. Endocrinology, 105:1930-1940,1980.
101. Ghanta, V. K., Hiramoto, R. N., Weiss, A. B., and Caudill, L. J. Monitoring of murine ostosarcoma by serial alkaline phosphatase determinations. J. Natl. Cancer Inst, 57:837-839,1976.
102. Reubi, J. C. A somatostatin analogue inhibits chondrosarcoma and insuli-noma tumour growth. Acta Endocrinol., 109:108-114,1985.
103. Minna, J. D. Neoplasms of the lung. In: E. Braunwald (eds.), Harri-son's Principles of Internal Medicine, Ed. 11, pp. 1115–1123. New York: McGraw-Hill Book Co., 1987.
104. Macauly, V. M., Teale, J. D., Everard, M. J., Joshi, G. P., Smith, I. E., and Millar, J. L. Somatomedin-C/insulin-like growth factor-I is a mitogen for human small cell lung cancer. Br. J. Cancer, 57:91-93,1988.
105. Taylor, J. E., Bogden, A. E., Moreau, J. P., and Coy, D. H. In vitro and in vivo inhibition of human small cell lung carcinoma (NC1-H69) growth by a somatostatin analog. Biochem. Biophys. Res. Commun., 153:81-86,1988.
106. Reubi, J. C., Maurer, R., Kljjn, J. G. M., Stefanko, S. Z., Foekens, J. A., Blaauw, G., Blankenstein, M. S., and Lamberts, S. W. J. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J. Clin. Endocrinol. Metab., 63:433-438,1986.
107. Libermann, A., Razon, N., Bartal, A. D., Yarden, Y., Schlessinger, J., and Soreq, H. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res., 44:753-760,1984.
108. Gammeltoft, S., Ballotti, R., Kowalski, A., Westermark, B., and Van Obberghen, E. Expression of two types of receptors for insulin-like growth factors in human malignant glioma. Cancer Res., 48:1233-1237,1988.
109. Banks, W. A., and Kastin, A. J. Peptides and the blood-brain barrier lipophilicity as a predictor of permeability. Brain Res. Bull., 15: 287–292, 1985.
110. Lippman, M. E., Dickson, E. B., Gelmann, E. P., Knappe, C., Kasid, A., Bates, S., and Swain, S. Mechanisms of estrogenic and antiestrogenic regulation of growth of human breast carcinoma. In: J. M. G. Klijn (ed.), Hormonal Manipulations of Cancer Peptides, Growth Factors and New (Anti)steroidal Agents, pp. 381–406. New York: Raven Press, 1985.
111. Sainsbury, J. R., Farndon, R., Needham, G., Malcolm, A., and Harris, A. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet, 1:1398-1402,1987.
112. Setyono-Han, B., Henkelman, M. S., Foekens, J. A., and Klijn, J. G. M. Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res., 47:1566-1570,1987.
113. Furlanetto, R. W., and DiCarlo, J. N. Somatomedin C receptors and growth effects in human breast cells maintained in long term culture. Cancer Res., 44:2122-2128,1984.
114. Kurachi, H., Okamoto, S., and Oka, T. Evidence for the involvement of the submandibular gland epidermal growth factor in mouse mammary tumorigenesis. Proc. Natl. Acad. Sci. USA, 82:5940-5943,1985.
115. Rose, D. P., Gottardis, M., and Noonan, J. J. Rat mammary carcinoma regressions during suppression of serum growth hormone and prolactin. Anticancer Res., 3:323-326,1983.
116. Redding, T. W., Fekete, M., and Schally, A. V. Direct inhibition of the MT-5 rat mammary tumor cell line by somatostatin analog RC-160. Abstract, Endocrine Society Meeting, New Orleans, June 1988, p. 171.
117. Bauknecht, T., Kiechle, M., Bauer, G., and Siebers, J. W. Characterization of growth factors in human ovarian carcinomas. Cancer Res., 46: 2614-2618,1986.
118. Parmar, H., Phillips, R. H., Rustin, G., Hanham, I. W., Schally, A. V., and Lightman, S. L. Response to D-Trp-6-LH-RH (decapeptyl) microcapsules in advanced ovarian cancer. Br. Med. J., 296:1229, 1988.
119. Walsh, P. C. Physiological basis for hormonal therapy in carcinoma of the nmstate. Ural. Clin. North Am. 7. 114—125
120. Geller, J., and Albert, J. D. Comparison of various hormonal therapies for prostatic carcinoma. Semin. Oncol., 10 (Suppl. 4).- 34-41,1983.
121. Parmar, H., Lightman, S. L., Allen, L., Phillips, R. H., Edwards, L., and Schally, A. V. Randomised controlled study of orchidectomy vs. long-acting D-Trp-6-LH-RH microcapsules in advanced prostatic carcinoma. Lancet, 2: 1201-1205,1985.
122. Isaacs, J. T., and Coffey, D. S. Adaption versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy studied in the Dunning R-3327-H adenocarcinoma. Cancer Res., 41:5070-5075,1981.
123. Johnson, M. P., Thompson, S. A., and Lubaroff, D. M. Differential effects of prolactin on rat dorsolateral prostate and R3327 prostatic tumor sublines. J. Urol., 133:1112-1120,1985.
124. Traish, B. M., and Wotiz, H. H. Prostatic epidermal growth factor receptors and their regulation by androgens. Endocrinology, 121:1461-1467,1987.
125. Maddy, S. Q., Chisholm, G. D., Hawkins, R. A., and Habib, F. K. Localization of epidermal growth factor receptors in the human prostate by biochemical and immunocytochemical methods. J. Endocrinol., 113: 147-153,1987.
126. Fekete, M., Csernus, V., Kadar, T., Redding, T. W., Ben-David, M., Pontes, J. E., and Schally, A. V. Receptors for prolactin, somatostatin, LHRH and growth factors in prostate cancer and BPH. Proc. Am. Assoc. Cancer Res., 29:248,1988.
127. Zalatnai, A., Paz-Bouza, J. I. Redding, T. W., and Schally, A. V. Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH. Prostate, 12:85-98,1988.